From Gut to Brain: A Longitudinal Assessment of Intestinal Permeability and Immune Activation Markers in Early-Stage Schizophrenia Spectrum Disorders
- 1National Institute of Mental Health, Czech Republic
Abstract
Schizophrenia spectrum disorders (SSD) have been linked to immune dysregulation and altered intestinal barrier function, although findings across studies remain inconsistent. The present study investigated circulating markers of intestinal permeability and immune activation in individuals with early-stage SSD and healthy controls and examined their associations with clinical outcomes. Serum concentrations of intestinal fatty acid-binding protein (iFABP), zonulin, soluble CD14 (sCD14), bactericidal/permeability-increasing protein (BPI), and lipopolysaccharide-binding protein (LBP) were measured in 36 patients with SSD at baseline and one-year follow-up and in 36 matched healthy controls. Linear mixed-effects models adjusted for age, sex, and body mass index (BMI) were used to evaluate group differences and longitudinal changes. No biomarker differences between patients and controls, and no longitudinal changes within patients, remained statistically significant after correction for multiple testing. Similarly, biomarker concentrations were not associated with symptom severity, global functioning, or neutrophil-to-lymphocyte ratio (NLR). Exploratory analyses identified a robust positive association between BMI and zonulin concentrations and additional associations among iFABP, LBP, and sCD14. Exploratory mixed-effects models identified a negative non-significant association between iFABP and sCD14 after adjustment for age, sex, and BMI. Overall, the findings do not support a generalized alteration of gut permeability or immune activation markers in SSD. Instead, they suggest that variation in gut-related biomarkers may be more strongly influenced by metabolic and individual factors than by diagnosis or current symptom severity.
Related
- Glial activation and increased blood brain barrier permeability in the medial preoptic area of male mice lacking neural androgen receptor
- Intestinal permeability and the zonulin pathway: tight junctions, mucosal immunity, dietary modulators and clinical relevance.
- A Retrospective Analysis of the Association Between Prediabetes and Biomarkers of Intestinal Permeability in Patients with Prediabetes from Durban, South Africa.
- Intestinal Permeability in Irritable Bowel Syndrome With and Without Comorbid Conditions: Results From the European DISCOvERIE Cohort.
- The Gut–Muscle Axis in Polycystic Ovary Syndrome: Proposed Mechanistic Roles of Intestinal Permeability, Bile Acid Signalling, and Skeletal Muscle Dysfunction
BibTeX
@misc{jakob2026from,
title = {{From Gut to Brain: A Longitudinal Assessment of Intestinal Permeability and Immune Activation Markers in Early-Stage Schizophrenia Spectrum Disorders}},
author = {L. Jakob and T. M. Mahayri and I. R. A. Koutrouli and K. Kekrtova and D. Novakova and T. Totkova and F. Spaniel},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.16.26364494},
url = {https://www.medrxiv.org/content/10.64898/2026.10.16.26364494v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - From Gut to Brain: A Longitudinal Assessment of Intestinal Permeability and Immune Activation Markers in Early-Stage Schizophrenia Spectrum Disorders
AU - L. Jakob
AU - T. M. Mahayri
AU - I. R. A. Koutrouli
AU - K. Kekrtova
AU - D. Novakova
AU - T. Totkova
AU - F. Spaniel
PY - 2026
DA - 2026/10/16
PB - medRxiv
DO - 10.64898/2026.10.16.26364494
UR - https://www.medrxiv.org/content/10.64898/2026.10.16.26364494v1
AB - Schizophrenia spectrum disorders (SSD) have been linked to immune dysregulation and altered intestinal barrier function, although findings across studies remain inconsistent. The present study investigated circulating markers of intestinal permeability and immune activation in individuals with early-stage SSD and healthy controls and examined their associations with clinical outcomes. Serum concentrations of intestinal fatty acid-binding protein (iFABP), zonulin, soluble CD14 (sCD14), bactericidal/permeability-increasing protein (BPI), and lipopolysaccharide-binding protein (LBP) were measured in 36 patients with SSD at baseline and one-year follow-up and in 36 matched healthy controls. Linear mixed-effects models adjusted for age, sex, and body mass index (BMI) were used to evaluate group differences and longitudinal changes. No biomarker differences between patients and controls, and no longitudinal changes within patients, remained statistically significant after correction for multiple testing. Similarly, biomarker concentrations were not associated with symptom severity, global functioning, or neutrophil-to-lymphocyte ratio (NLR). Exploratory analyses identified a robust positive association between BMI and zonulin concentrations and additional associations among iFABP, LBP, and sCD14. Exploratory mixed-effects models identified a negative non-significant association between iFABP and sCD14 after adjustment for age, sex, and BMI. Overall, the findings do not support a generalized alteration of gut permeability or immune activation markers in SSD. Instead, they suggest that variation in gut-related biomarkers may be more strongly influenced by metabolic and individual factors than by diagnosis or current symptom severity.
ER -